Early interventional work, including a prospective feasibility study in diuretic-resistant ascites and a randomized trial in refractory ascites, suggests that add-on SGLT2 inhibition can facilitate ascites control and reduce the need for large-volume paracentesis over short horizons, provided careful selection and monitoring are applied [27,128]. The gene discussed is SLC5A2; the disease is Ascites.